Skip to main content
. 2016 Nov 9;29:172–175. doi: 10.1016/j.ijscr.2016.11.006

Fig. 5.

Fig. 5

Axial view of follow-up MRI. MRI of the pelvis obtained four months after resuming imatinib demonstrated decrease in the size of the right corpus cavernosum mass from 8.4 × 4.3 × 3.6 cm to 4.9 × 1.8 × 1.5 cm.